On Wednesday, Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s shares inclined 0.83% to $2.42.
Orexigen Therapeutics, Inc. (OREX) declared receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen’s United States partner for Contrave® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are predictable from Takeda in the fourth quarter of each of 2016 and 2017.
Orexigen also declared receipt of the $7 million upfront payment from Kwang Dong Pharmaceutical Company Ltd., based in Seoul, Korea. In August 2015, Orexigen and Kwang Dong executed a Korean distributorship agreement for Contrave. Kwang Dong anticipates to start marketing Contrave in the second half of 2016, if regulatory approval is obtained.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a partnership agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Autodesk, Inc. (NASDAQ:ADSK)’s shares dropped -0.02% to $46.92.
Autodesk, Inc. (ADSK) declared that it will broadcast a webcast in conjunction with its forthcoming Investor Day event on Tuesday, 29 September, 2015 at 8:30 a.m. Pacific Time. Carl Bass, Autodesk president and CEO, will be joined by other Autodesk senior executives to talk about with the investment community the opportunities in the current market, provide updates on the business model transition, financial metrics, and corporate strategy.
Autodesk, Inc. operates as a design software and services company worldwide. The company’s Architecture, Engineering and Construction segment offers Autodesk Building Design Suites to manage various phases of design and construction; Autodesk Revit products that provide model-based design and documentation systems; Autodesk Infrastructure Design Suites; AutoCAD Civil 3D products that offer a surveying, design, analysis, and documentation solution; and AutoCAD Map 3D software, which offers direct access to data needed for infrastructure planning, design, and administration.
At the end of Wednesday’s trade, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)‘s shares surged 0.71% to $8.56.
Achillion Pharmaceuticals, Inc. (ACHN) declared additional interim results from a Phase 2 study evaluating odalasvir (also known as ACH-3102), a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. Of the patients treated for six weeks in this cross-over cohort, 100 percent (n=6/6) remained HCV RNA undetectable twelve weeks after concluding therapy (SVR12). Formerly, Achillion stated results from this study counting 100 percent SVR24 for the initial cohorts counting 12 patients treated for eight weeks and 100 percent SVR24 for 12 patients treated for six weeks.
In May 2015, Achillion declared it had granted Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets which comprise odalasvir, ACH-3422, and sovaprevir.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
Youku Tudou Inc (ADR) (NYSE:YOKU), ended its Wednesday’s trading session with -2.20% loss, and closed at $16.02.
Youku Tudou, Inc. (YOKU), a leading multi-screen entertainment and media company in China, declared that it has reached a content licensing agreement with Paramount Pictures that will bring more than a hundred top titles from Paramount Picture’s film library to Youku Tudou. Popular franchises and titles such as Transformers, Shrek, Star Trek, Mission: Impossible and Forrest Gump will be viewable through Youku Tudou’s subscription service and select future Paramount releases will be accessible through TVOD.
Youku Tudou’s subscription service presently offers a wide selection of content from both foreign and domestic studios. More licensed content in addition to Youku Tudou web-native content will be added on an ongoing basis, continually enriching the value proposition of the Company’s subscription services.
Youku Tudou Inc. operates as an Internet television company in the People’s Republic of China. Its Internet television platform enables users to search, view, and share video content across various devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
